Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

▤ Summary

Coherus Oncology and Zumutor Biologics have entered a clinical collaboration and supply agreement to test ZM008 with LOQTORZI in a Phase 1 combination trial. The study will enroll up to 45 patients across several solid tumor types in the United States. Coherus will supply LOQTORZI, while Zumutor will sponsor the trial and keep commercial rights to its compound. The collaboration is positioned as a step to expand LOQTORZI’s potential indications and strengthen clinical evidence for future development.

▦ Linked Companies